Trent D Lund

US Patent:

8450364, May 28, 2013

Filed:

Apr 9, 2012

Appl. No.:

13/442466

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US

Assignee:

Brigham Young University - Provo UT
Colorado State University Research Foundation - Fort Collins CO
Children's Hospital Medical Center of Cincinnati, Ohio - Cincinnati OH

International Classification:

A61K 31/35

US Classification:

514456

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20050245492, Nov 3, 2005

Filed:

Feb 17, 2005

Appl. No.:

11/059951

Inventors:

Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth Reginald Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US

International Classification:

A61K031/56

US Classification:

514170000

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

US Patent:

20060122262, Jun 8, 2006

Filed:

Oct 29, 2003

Appl. No.:

10/533045

Inventors:

Edwin Lephart - Orem UT, US
Trent Lund - Wheaton IL, US
Kenneth David Setchell - Cincinnati OH, US
Robert Handa - Fort Collins CO, US

International Classification:

A61K 31/353

US Classification:

514456000

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20100087519, Apr 8, 2010

Filed:

Oct 2, 2009

Appl. No.:

12/572791

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US

International Classification:

A61K 31/353
A61P 43/00

US Classification:

514456

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20160256436, Sep 8, 2016

Filed:

Mar 9, 2016

Appl. No.:

15/065344

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US

International Classification:

A61K 31/353
A61K 9/00
A61K 8/49
A61Q 19/08
A61Q 7/00

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20150342924, Dec 3, 2015

Filed:

Jul 27, 2015

Appl. No.:

14/810117

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Robert J. Handa - Fort Collins CO, US

International Classification:

A61K 31/353
A23L 1/30

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20140135387, May 15, 2014

Filed:

May 28, 2013

Appl. No.:

13/903748

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - Wheaton IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Fort Collins CO, US

Assignee:

Brigham Young University - Provo UT
Children's Hospital Center - Cincinnati OH
Colorado State University Research Foundation - Fort Collins CO

International Classification:

A61K 31/352

US Classification:

514456

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

US Patent:

20100076071, Mar 25, 2010

Filed:

Jul 31, 2009

Appl. No.:

12/533169

Inventors:

Edwin Douglas Lephart - Orem UT, US
Trent D. Lund - St. Charles IL, US
Kenneth David Reginald Setchell - Cincinnati OH, US
Robert J. Handa - Phoenix AZ, US

International Classification:

A61K 31/352
A61P 5/26

US Classification:

514456

Abstract:

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.